Percentage of Novartis pharmaceuticals revenue by therapy area 2023

In 2023, Novartis AG generated around 30 percent of its revenue through its oncology division. About the same percentage of the company’s total revenue was earned through its established brands division.

Sandoz

Novartis AG’s Promoted brands was the company’s largest segment in 2023. In that year, this segment earned the company 31.8 billion U.S. dollars. The other segment is Established brands, generating some 13.6 billion dollars in the same year. The Sandoz division, which creates generic pharmaceuticals and biosimilars, was spun-off in mid-2023, becoming an separate company. Around 74 percent of Novartis' revenues were generated in established markets, while the remainder was earned in emerging growth markets.

Novartis R&D spending

Novartis AG spent around 11.4 billion U.S. dollars on research and development in 2023. The highest R&D expenses in relation to sales was reported for 2023. That year’s R&D expenditures accounted for roughly one quarter of the company’s total revenue.